Are RNA vaccines really Vaccines?
Answers from top 9 papers
More filters
| Papers (9) | Insight |
|---|---|
126 Citations | Expert opinion: The prospects for mRNA vaccines are very promising. |
| As new cancer antigens come to the forefront with novel RNA encapsulation and targeting techniques, RNA vaccines may prove to be a vital, safe and robust method to initiate patient-specific anti-tumor efficacy. | |
15 Citations | This suggests that protein-based vaccines formulated using RNA adjuvant function as live-attenuated vaccines. |
394 Citations | Naked, non-infectious, self-replicating RNA may be an excellent candidate for the development of new cancer vaccines. |
16 Citations | Based on experience in recent clinical trials, mRNA-based vaccines are a promising novel platform that might be useful for the development of vaccines against emerging pandemic infectious diseases. |
| Possible drawbacks related to the cost and feasibility of manufacturing RNA vaccines are being addressed, increasing the likelihood that RNA-based vaccines will be commercially viable. | |
| From this we conclude that sa-RNA is a promising platform for vaccines against viral diseases. | |
15 Citations | Therefore, RNA adjuvants have broad applicability and can be used with all conventional vaccines to improve vaccine efficacy qualitatively and quantitively. |
19 Oct 2017 161 Citations | Notably, our data demonstrate that mRNA vaccines can compete with licensed vaccines based on inactivated virus or are even superior in respect of functional antibody and T cell responses. |